This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

R. Kartzinel, MD; D. B. Calne, MD
National Institutes of Health Bethesda, MD 20014

Arch Neurol. 1977;34(1):59.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

We thank Drs Tolosa and Sparber for their comments concerning our article "Bromocriptine in Huntington Chorea," which recently appeared in the ARCHIVES (33:517, 1976). In our study, doses greater than 40 mg of bromocriptine were not "toxic"; there was simply a conventional sigmoid dose-response relationship for the induction of chorea in both parkinsonian and huntingtonian patients. We could not find any evidence to support the view that the dopaminergic agonist that we were studying, bromocriptine, had any therapeutic action in Huntington disease. We do not take issue with Drs Tolosa's and Sparber's observations with apomorphine or to its possible mechanisms of action. We are confident that dopamine-receptor agonists like bromocriptine will lead to progress in the treatment of parkinsonism, but we are not as optimistic as Drs Tolosa and Sparber about their effectiveness in Huntington chorea. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?